Toxic Tau: Who Are You, and Where Are You From?
Recent conferences revealed that tau is most toxic in oligomeric form, that tau oligomers propagate throughout the brain, and that tau oligomers might harm synapses from within or via astrocytes.
ALL NEWS
6535 RESULTS
Sort By:
- Most Recent
- Most Commented
Tau, α-Synuclein Spread: Crazy Stuff—How Might It Work?
Many researchers believe that neurodegeneration's takeover of one's brain might be driven by pathogenic, misfolded proteins spreading through interconnected neural networks...
Gearing Up for Down’s Syndrome Clinical Trials
Longitudinal studies in DS have pegged biomarkers and cognitive measures as potential clinical trial readouts. Hundreds of adults are anticipated to join trial-ready cohorts this year.
What Drives Tangles to Spread? Answers Start Rolling In
Soluble p-tau, aggregation epicenters, and gene variants emerged as potential forces that might influence how quickly tangles propagate through the brain.
Meta-Analysis of RNA-Seq Data is Robust, Finds Key Changes in AD
By pooling single-nucleus RNA-sequencing datasets, scientists found consistent changes across Alzheimer’s cohorts. Examples: hypermetabolic transcription, and a new neuron population that dies early on.
Alzheimer's Association International Conference (AAIC)- 2022
Crenezumab Secondaries Negative; Gantenerumab OLE Hints at Efficacy Can BACE Inhibitors Stage a Comeback? High-Res Spatial Transcriptomics Offers New Views of Mouse Brain Alzheimer's Blood Tests Have Arrived; Road to Broad Use Still Stretches On Bloo
Windfall Week for Trial Data: Papers on Crenezumab, Neflamapimod, Tofersen
Three drugs, targeting three different pathogenic mechanisms in Alzheimer's, dementia with Lewy bodies, and ALS, had trial data formally published this week.
As DIAN Wraps Up Anti-Aβ Drug Arms, it Sprouts Tau, Primary Prevention Arms
The DIAN Trials Unit is nearing the end of its first two secondary prevention trials. It has begun a cognitive run-in period for its next trial, of a tau-based drug, and for a primary prevention study in people as young as 18.
FDA Approves ALS Drug on Phase 2 Data
The agency, under pressure from advocacy groups, considers uncertainty about efficacy to be acceptable.
Sharp at 100+? Thank You, Genes. Thank You, Immune System.
Staying lucid as a centenarian may depend on the immune system you inherit.
Kuopio Alzheimer Symposium (9th) and Nordic Memory Clinic Conference (3rd)
Sharp at 100+? Thank You, Genes. Thank You, Immune System. In Hydrocephalus, Does Slow Drainage Cause Dementia? Differential Diagnosis: Can Synaptic Proteins Get It Done? Kuopio Alzheimer Symposium (9th) and Nordic Memory Clinic Conference (3rd)
Another Study Links Daily Steps with Better Health
Middle-aged people who strode 8,000+ steps a day were less likely to have a range of conditions, including diabetes and hypertension.
DC: Protein Work Expands ALS/FTD Genetics
At a satellite of the annual meeting of the Society for Neuroscience, researchers reported big new discoveries in ALS genetics...
Crenezumab Secondaries Negative; Gantenerumab OLE Hints at Efficacy
At AAIC, secondary endpoint data from the API Colombian study showed trends favoring crenezumab, while people taking gantenerumab in open-label extensions declined more slowly than matched controls.
Up-and-Coming Immunotherapies Target Aβ and Tau
Scientists are testing passive and active immunotherapies that take down pyroglutamate Aβ, and a combo Aβ/tau vaccine.
Current Filters
No filters selected